Aurora Cannabis Reaffirms Recommendation to Shareholders: REJECT Curaleaf's Revised Hostile Bid; Preserve Opportunities for Future Upside

Impact · against what's priced in

Aurora Cannabis is attempting to drive a higher valuation by leveraging its debt-free status and engaging third-party bidders to counter Curaleaf's hostile bid. While this creates potential upside for ACB through a bidding war, it presents a headwind for CURA as its current offer is deemed inadequate by the target board.

ACB+0.30

No priced-in read yet